# Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)

> **NCT03635086** · PHASE2 · COMPLETED · sponsor: **Themis Bioscience GmbH** · enrollment: 60 (actual)

## Conditions studied

- Chikungunya Virus Infection

## Interventions

- **BIOLOGICAL:** MV-CHIK lyophilised formulation, low dose
- **BIOLOGICAL:** MV-CHIK liquid frozen formulation, low dose
- **BIOLOGICAL:** MV-CHIK SPS® formulation, low dose
- **BIOLOGICAL:** MV-CHIK liquid frozen formulation, high dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03635086
- **Lead sponsor:** Themis Bioscience GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-22
- **Primary completion:** 2019-01-25
- **Final completion:** 2019-11-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635086, "Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03635086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*